Julieann I. Puleo

Julieann I. Puleo

Auto-generated profile, based on publicly available information

Julieann I. Puleo

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DTDanh Truong
Danh Truong
JPJulieann Puleo
Julieann Puleo
ALAlison Llave
Alison Llave
GMGhassan Mouneimne
Ghassan Mouneimne
RKRoger D. Kamm
Roger D. Kamm
MNMehdi Nikkhah
Mehdi Nikkhah
In this study, to model 3D chemotactic tumor-stroma invasion in vitro, we developed an innovative microfluidic chip allowing side-by-side positioning of 3D hydrogel-based matrices. We were able to (1) create a dual matrix architecture that extended in a continuous manner, thus allowing invasion from one 3D matrix to another and (2) establish distinct regions of tumor and stroma cell/ECM compositions, with a clearly demarcated tumor invasion front, thus allowing us to quantitatively analyze progression of cancer cells into the stroma at a tissue or single-cell level. We showed significantly enhanced cancer cell invasion in response to a transient gradient of epidermal growth factor (EGF). 3D tracking at the single-cell level displayed increased migration speed and persistence. Subsequently, we analyzed changes in expression of EGF receptors, cell aspect ratio and protrusive activity. These findings show the unique ability of our model to quantitatively analyze 3D chemotactic invasion, both globally by tracking the progression of the invasion front and at the single-cell level by examining changes in cellular behavior and morphology using high-resolution imaging. Taken together, we have shown a novel model recapitulating 3D tumor-stroma interactions for studies of real-time cell invasion and morphological changes within a single platform.

8 October 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
JPJulieann I. Puleo
Julieann I. Puleo
SPSara S. Parker
Sara S. Parker
MRMackenzie R. Roman
Mackenzie R. Roman
AWAdam W. Watson
Adam W. Watson
KEKiarash Rahmani Eliato
Kiarash Rahmani Eliato
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
The mechanical properties of a cell’s microenvironment influence many aspects of cellular behavior, including cell migration. Durotaxis, the migration toward increasing matrix stiffness, has been implicated in processes ranging from development to cancer. During durotaxis, mechanical stimulation by matrix rigidity leads to directed migration. Studies suggest that cells sense mechanical stimuli, or mechanosense, through the acto-myosin cytoskeleton at focal adhesions (FAs); however, FA actin cytoskeletal remodeling and its role in mechanosensing are not fully understood. Here, we show that the Ena/VASP family member, Ena/VASP-like (EVL), polymerizes actin at FAs, which promotes cell-matrix adhesion and mechanosensing. Importantly, we show that EVL regulates mechanically directed motility, and that suppression of EVL expression impedes 3D durotactic invasion. We propose a model in which EVL-mediated actin polymerization at FAs promotes mechanosensing and durotaxis by maturing, and thus reinforcing, FAs. These findings establish dynamic FA actin polymerization as a central aspect of mechanosensing and identify EVL as a crucial regulator of this process.

30 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMarco Padilla-Rodriguez
Marco Padilla-Rodriguez
SPSara S. Parker
Sara S. Parker
DADeanna G. Adams
Deanna G. Adams
TWThomas Westerling
Thomas Westerling
JPJulieann I. Puleo
Julieann I. Puleo
Ghassan (Gus) MouneimneGhassan (Gus) Mouneimne
Ghassan (Gus) Mouneimne
Estrogen promotes growth of estrogen receptor-positive (ER+) breast tumors. However, epidemiological studies examining the prognostic characteristics of breast cancer in postmenopausal women receiving hormone replacement therapy reveal a significant decrease in tumor dissemination, suggesting that estrogen has potential protective effects against cancer cell invasion. Here, we show that estrogen suppresses invasion of ER+ breast cancer cells by increasing transcription of the Ena/VASP protein, EVL, which promotes the generation of suppressive cortical actin bundles that inhibit motility dynamics, and is crucial for the ER-mediated suppression of invasion in vitro and in vivo. Interestingly, despite its benefits in suppressing tumor growth, anti-estrogenic endocrine therapy decreases EVL expression and increases local invasion in patients. Our results highlight the dichotomous effects of estrogen on tumor progression and suggest that, in contrast to its established role in promoting growth of ER+ tumors, estrogen has a significant role in suppressing invasion through actin cytoskeletal remodeling.

27 November 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JNJun Nishida
Jun Nishida
SCSimona Cristea
Simona Cristea
SBSudheshna Bodapati
Sudheshna Bodapati
JPJulieann Puleo
Julieann Puleo
GBGali Bai
Gali Bai
KPKornelia Polyak
Kornelia Polyak
Immune escape is a prerequisite for tumor growth. We previously described a decline in intratumor activated cytotoxic T cells and T cell receptor (TCR) clonotype diversity in invasive breast carcinomas compared to ductal carcinoma in situ (DCIS), implying a central role of decreasing T cell responses in tumor progression. To determine potential associations between peripheral immunity and breast tumor progression, here, we assessed the peripheral blood TCR clonotype of 485 breast cancer patients diagnosed with either DCIS or de novo stage IV disease at younger (<45) or older (≥45) age. TCR clonotype diversity was significantly lower in older compared to younger breast cancer patients regardless of tumor stage at diagnosis. In the younger age group, TCR-α clonotype diversity was lower in patients diagnosed with de novo stage IV breast cancer compared to those diagnosed with DCIS. In the older age group, DCIS patients with higher TCR-α clonotype diversity were more likely to have a recurrence compared to those with lower diversity. Whole blood transcriptome profiles were distinct depending on the TCR-α Chao1 diversity score. There were more CD8 + T cells and a more active immune environment in DCIS tumors of young patients with higher peripheral blood TCR-α Chao1 diversity than in those with lower diversity. These results provide insights into the role that host immunity plays in breast cancer development across different age groups.